Skip to main content
. 2010 Oct 11;107(43):18593–18598. doi: 10.1073/pnas.1005582107

Fig. 5.

Fig. 5.

Anti–DNAM-1 mAb ameliorated overt acute GVHD. (A and B) B6C3F1 mice received splenocytes from WT B6 mice after sublethal irradiation. The recipient mice were injected i.p. with 300 μg anti–DNAM-1 (TX42) (n = 11) or control antibodies (n = 11) every week from day 14 until day 77 after transplantation (A), or 1.0 mg TX42 (n = 19) or control antibodies (n = 19) once on day 14 (B). B6C3F1 mice that received irradiation only are also shown (n = 8 or 9). (C) C3 mice were transplanted with bone marrow cells and spleen T cells from B6 mice after lethal irradiation. The recipient C3 mice were injected i.p. with 1.0 mg TX42 (n = 8) or control antibodies (n = 8) once on day 14. Recipient B6 mice that received transplantation with bone marrow cells and T cells after lethal irradiation (Syngeneic BMT) are also shown (n = 6). Data are representative of two independent experiments with similar results in A. Data are pooled from two independent experiments in B and C.